BXCL501 After Stress to Increase Recovery Success
Phase 2
100
about 1.1 years
18–65
3 sites in FL, MO, VA
About this study
This trial is testing if BXCL501 helps reduce symptoms of Acute Stress Reaction (ASR) and Acute Stress Disorder (ASD) in adults who have experienced a motor vehicle collision. Participants will receive BXCL501 or a placebo after the accident, and their symptoms, cognitive function, and any side effects will be monitored over 396 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take BXCL501 (dexmedetomidine HCl)
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
dexmedetomidine, Anesthetics (Adrenergic alpha1-Agonists)
Secondary: Change in Depressive Symptoms Score, Change in PTSD Symptoms, Change in Pain Symptom Score, Change in Somatic Symptom Score
Psychiatry / Mental Health